Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Price

APLSStock
$0.002.20%52W
Market Cap
P/E234.62x
PEG Ratio
Div yield
Beta-0.08

APLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)96.11%
Price vs S&P 500 (4W)-5.40%
VGM Score60.13
P/E Ratio (Annual)234.62x

APLS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.41
3.41
3.41
3.41

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
APLSApellis Pharmaceuticals, Inc. Common Stock
DBB$0.00
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Apellis Pharmaceuticals, Inc. Common Stock

Apellis Pharmaceuticals commercializes complement system inhibitors for diseases with significant unmet treatment needs. The company markets two C3-targeted therapies, SYFOVRE and EMPAVELI (both pegcetacoplan-based), which inhibit a central immune pathway and represent meaningful commercial opportunities in complement-driven immune diseases.